Endocrine Abstracts

Introduction: We investigated the levels of IGF1 in acute myocardial infarction (AMI) and sought to determine whether a decrease might influence the long-term prognosis.

Material and methods: Sixty-five patients who were admitted to our hospital with AMI were included in the study along with 26 other patients without coronary artery disease (CAD) who served as the control group. Fasting blood samples of all of the patients with AMI were obtained at the hospital and ~10 months later in order to evaluate their IGF1 and IGF-binding protein 3 (IGFBP3) levels.

Results: In the patients with AMI, the IGF1 levels were higher than in the control group (P=0.002). At the 10th month, the levels of IGFBP3 were significantly higher, and the IGF1 levels were higher but were not more significant than those in the control group (P=0.006 and P=0.05 respectively). When we compared the 10-month and baseline values, the levels of IGFBP3 were significantly higher at 10 months. In addition, the IGF1 levels were lower but did not achieve significance at 10 months (P=0.04) or at the time baseline measurements were taken (P=0.06). Furthermore, no significant differences were found between the patients with low or high IGF1 and IGFBP3 levels at the two different time periods when they were compared in terms of cardiac events.

Conclusion: At the 10-month follow-up after AMI, the serum total IGF1 and IGFBP3 levels were still high, and no correlations existed between the IGF1 and IGFBP3 levels and cardiac events.